AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04656405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online real-time quality measurement and feedback video-based CPR training
Description: Participants in the online real-time quality measurement and feedback video-based CPR training program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. The study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) are provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing and collect real-time performance data using the QCPR mannequin device. Using this information, the instructor will provide real-time online feedback to participants.
Study NCT04656405 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online real-time feedback video-based CPR training without quality measurement
Description: Participants in the online real-time feedback video-based CPR training without quality measurement program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. When study participants access the online training center, study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) is provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing. The instructor will provide real-time online feedback to participants.
Study NCT04656405 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional CPR training
Description: Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) device are provided to measure and give feedback on the participants CPR performance.
Study NCT03428997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotion
Description: Formulated Lotion F# 13451-131 was applied on an occlusive patch and placed on a test site on each subjects back three times a week for four weeks.
Study NCT03428997 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Negative Control
Description: Control. An undosed occlusive patch was placed on a test site on each subjects back three times a week for four weeks.
Study NCT03368625 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Radiosurgery
Description: Stereotactic Radiosurgery before surgical resection of brain mets.
Study NCT02424812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifebuoy School of Five Handwashing Intervention
Study NCT01947959 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, Bay59-7939)
Description: The treatment of DVT or PE, and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\]).
Study NCT01947959 — intervention group
Intervention type: DRUG
Intervention: Standard of care
Description: For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
Study NCT03893981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioception and Balance Program
Description: Balance Trainer device and playing ball in tandem position for using to improve balance, vibration and reposition exercises for using to improve proprioception. Progressive of training will increase after each 2 weeks.Patients will be taken to the treatment program 3 days in a week for 8 weeks.
Study NCT03893981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening Program
Description: Exercises which include open and closed kinetic chain exercise will be applied to strength knee and hip muscle. Progressive of training will increase after each 2 weeks. Patients will be taken to the treatment program 3 days in a week for 8 weeks.
Study NCT03329599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polycap
Description: Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
Study NCT01459666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dysport (abobotulinumtoxinA)
Description: Intramuscular injection effects lasting up to 3 months
Study NCT01459666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bacteriostatic 0.9% Sodium Chloride (vehicle)
Description: Intramuscular injection
Study NCT01061385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReShape Intragastric Balloon
Description: Placement of ReShape Medical Intragastric Balloon for twenty four weeks
Study NCT01061385 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Arm
Description: Behavioral Modification (Diet and exercise counseling) alone
Study NCT03586271 — intervention group
Intervention type: PROCEDURE
Intervention: trifocal lens
Description: phacoemusification + trifocal lens(AT Lisa tri 839MP) implantation
Study NCT03771404 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: Patients' peripheral blood will be obtained before the surgical excision of the primary tumor as well as 1-month post-op and every 3-6 months thereafter until disease progression and upon disease relapse for the evaluation of ctDNA and CTCs. Different sites of the primary tumor as well as the regional involved lymph nodes and, in selected patients, biopsies from metastatic sites will be genotyped by NGS as well.
Study NCT03586271 — intervention group
Intervention type: PROCEDURE
Intervention: bifocal lens 1
Description: phacoemusification +bifocal lens(Diff-aay) implantation
Study NCT03586271 — intervention group
Intervention type: PROCEDURE
Intervention: bifocal lens 2
Description: phacoemusification +bifocal lens (ReSTOR +3.0D) implantation
Study NCT03586271 — intervention group
Intervention type: PROCEDURE
Intervention: bifocal lens 3
Description: phacoemusification +bifocal lens (ReSTOR +2.5D) implantation
Study NCT03018808 — intervention group
Intervention type: OTHER
Intervention: CAT
Description: The CAT is a questionnaire for COPD patients and is designed to measure the impact of COPD on a person's life over time.
Study NCT01165034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathlessness Support Service
Description: Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
Study NCT00776399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung radiofrequency ablation
Description: A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
Study NCT04169464 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir Oral Product
Description: to investigate the drug effect on renal function and insulin resistance
Study NCT00202696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalmefene
Description: Nalmefene HCl film-coated tablets administered orally, twice daily, for total daily dosage of 40 or 80 mg, for 5 weeks (following a 2-week titration period).
Study NCT02584868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution
Description: Peri-operative fluid replacement therapy (max 40ml/kg/day)
Study NCT02584868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethyl starch 130/0.4 in 0.9% sodium chloride
Description: Peri-operative fluid replacement therapy (max 40ml/kg/day)
Study NCT02814695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vit E
Description: 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (2 mg/ml) Vitamin E and incubated at 37o C for 30 minutes.
Study NCT02814695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yeast
Description: 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (20 mg/ml) yeast extraction and incubated at 37o C for 30 minutes.
Study NCT00202696 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo tablets, administered orally, twice daily for 5 weeks (following a 2-week titration period).
Study NCT03809273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangxinshi
Description: Yangxinshi pill 3 pills /tid
Study NCT03809273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimetazidine
Description: Trimetazidine 20mg/tid
Study NCT03809273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yangxinshi mimic
Description: Yangxinshi mimic tablets 3 pills /tid
Study NCT03018808 — intervention group
Intervention type: PROCEDURE
Intervention: Blood test
Description: Blood samples will be collected at indicated time points
Study NCT02814695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vit C 1
Description: 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.02 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
Study NCT02814695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vit C 2
Description: 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.04 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
Study NCT02814695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vit C 3
Description: 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.06 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
Study NCT01803711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Study NCT01803711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine
Study NCT01803711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 Fatty acids
Study NCT01803711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Omega 3 fatty acid supplement)
Study NCT03809273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine mimic
Description: Trimetazidine mimic tablets 20mg/tid
Study NCT01645085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-based 13% drug loaded tablets
Description: 50mg tablets, dosed as 2 tablets (100mg total)
Study NCT01768949 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Echocardiography
Description: In the study RVSTAR, all the patients included will undergo an echocardiography in order to find an echocardiographic criterion predictive of the inefficacy and/or unsafeness of recruitment maneuver.
Study NCT04024826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFP
Description: This group will perform the Resistance training intervention on day 4 of the menstrual cycle, which corresponds to the mid of early follicular phase.
Study NCT01645085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol-based 38% drug-loaded tablet
Description: One 100mg tablet
Study NCT01645085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-based 13% drug loaded tablets
Description: 3 tablets (150mg total)
Study NCT01645085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol-based 38% drug-loaded tablet
Description: One 150 mg tablet
Study NCT03056807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 25° head-up position
Description: Angle person is positioned for procedure.
Study NCT03056807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 55° head-up position
Description: Angle person is positioned for procedure.
Study NCT02907671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carpal tunnel corticoanesthetic injection
Description: Different Injection Sites (between the flexot tendons or around the median nerve with hydrodissection)
Study NCT03018808 — intervention group
Intervention type: OTHER
Intervention: anthropometric measures
Description: Anthropologic measures will be performed.
Study NCT04467632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Validation of the mobility assessment by IMU wearable sensors
Description: The validity of the mobility assessment by IMU wearable sensors will be verified in Work Package 3.~It will be defined as the accuracy of the machine learning algorithm to predict patients' motor status compared to the motor status assessed at clinical examination by means of the MDS-UPDRS-III scale and the Fit test. Prediction by machine learning will be compared with the MDS-UPDRS-III total score and with the 3.14 item (global clinical impression of mobility) of the same scale.~The patients will be asked to perform all the motor tasks of the MDS-UPDRS-III scale and the finger tapping test (Fit test) with both hands wearing the IMU system. A subset of minimal motor tasks allowing good prediction of the patient's motor status by the machine learning algorithm will then be selected for Work Package 4.
Study NCT04467632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing in real-life conditions at patients' home in a small group of subjects
Description: Baseline Phase B1: Observation phase: 1-week wrist actigraphy and sleep diary to assess habitual activity/rest routines.~B2: Nocturnal sleep consolidation phase: 2 weeks: timed light exposure, constant sleep/wake routine and sleep restriction of 1 hour/night (based on habitual activity).
Study NCT04467632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing in real-life conditions at patients' home in a small group of subjects
Description: Intervention phase~* Phase A (11 days): subjects will receive one hour of morning and afternoon light exposure twice a day:~  * Day #1: baseline assessment of outcome measures;~ * Days #2 to #6: bright light in the morning (active treatment) + dim light in the afternoon (placebo), to progressively advance circadian phase of 30' per day (phase advance of 2.5 hours obtained at day 6);~ * Days #7 to #11: dim light in the morning + bright light in the afternoon to revert the circadian phase to the baseline of 30' per day.~* Washout: 6 days. No intervention during this phase, to stabilise the reverted circadian rhythm to baseline, for phase B to be held at the same conditions as phase A.~* Phase B (11 days): similar as in phase A:~  * Day #1: similar as in phase A;~ * Days #2 to #6: reverted conditions compared to phase A.~ * Days #7 to #11: reverted conditions compared to phase A.
Study NCT02823041 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: 24 weeks of systematic computerized cognitive training, 4 hours per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations.
Study NCT02823041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: 24 weeks of systematic computerized cognitive training, 4 hours per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations.
Study NCT02823041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise occurs as two 45-minute sessions at the clinic and two 30-minute sessions at home weekly. Exercise involves an adaptation of interval training, including a variety of calisthenics that can be done without specialized equipment. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
Study NCT02823041 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case management and supportive psychotherapy
Description: An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
Study NCT02823041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management and supportive psychotherapy
Description: An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
Study NCT02823041 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Placement and Support
Description: An job/school specialist will use the Individual Placement and Support model to help participants return to school or work and provide ongoing outreach support.
Study NCT03018808 — intervention group
Intervention type: OTHER
Intervention: Oximetry
Description: Digital pulse oximeter on the index finger after five minutes rest and before receiving bronchodilator for spirometry will be used to measure the pulse arterial oximetry. The average of three measurements at 10 second intervals will be recorded. The heart rate will be provided by the pulse oximeter.
Study NCT01490931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Nasal Spray
Description: 15.75 mg nasal spray delivery to each nostril no more than every six hours
Study NCT00307034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' 10-valent pneumococcal conjugate vaccine.
Description: Intramuscular injection, 3 or 4 doses (2-4-11 or 2-3-4-11 months of age schedule).
Study NCT02823041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support
Description: An job/school specialist will use the Individual Placement and Support model to help participants return to school or work and provide ongoing outreach support.
Study NCT02307539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychosocial Assessment and Care
Description: Undergo PCPI
Study NCT02307539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Undergo PCPI
Study NCT02307539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Undergo QOL assessment
Study NCT02307539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Undergo questionnaire administration
Study NCT01064219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotrophin
Description: intrauterine injection of 100 IU hCG followed by endometrial biopsy .
Study NCT02195934 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard (blonde) orange juice
Description: Consumption of 500ml standard (blonde) orange juice daily for 28 days
Study NCT02195934 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood orange juice
Description: Consumption of 500ml blood orange juice daily for 28 days
Study NCT03312868 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiotherapy
Study NCT00307034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa.
Description: Intramuscular injection, 3 doses (2-4-11 months of age schedule).
Study NCT00307034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib.
Description: Intramuscular injection, 3 doses (2-4-11 months of age schedule).